(Q80298001)

PubMed publication ID

16986000

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16986000%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

Androgen deprivation and other treatments for advanced prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1476080&resulttype=core&format=json

10 May 2020

1 reference

Brawer MK

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1476080&resulttype=core&format=json

10 May 2020

Crawford ED

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1476080&resulttype=core&format=json

10 May 2020

Labrie F

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1476080&resulttype=core&format=json

10 May 2020

Mendoza-Valdes A

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1476080&resulttype=core&format=json

10 May 2020

Miller PD

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1476080&resulttype=core&format=json

10 May 2020

Petrylak DP

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1476080&resulttype=core&format=json

10 May 2020

publication date

1 January 2001

1 reference

PubMed publication ID

16986000

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16986000%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1476080&resulttype=core&format=json

10 May 2020

volume

3 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1476080&resulttype=core&format=json

10 May 2020

page(s)

S59-68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1476080&resulttype=core&format=json

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

10 May 2020

cites work

1 reference

12 December 2020

Flutamide Eliminates the Risk of Disease Flare in Prostatic Cancer Patients Treated with a Luteinizing Hormone-Releasing Hormone Agonist

1 reference

12 December 2020

Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

1 reference

12 December 2020

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

12 December 2020

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

1 reference

12 December 2020

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines

1 reference

12 December 2020

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.

1 reference

12 December 2020

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

12 December 2020

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

12 December 2020

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

12 December 2020

Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells.

1 reference

12 December 2020

Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies

1 reference

12 December 2020

Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial

1 reference

12 December 2020

Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.

1 reference

12 December 2020

Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.

1 reference

12 December 2020

Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer

1 reference

12 December 2020

Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Alendronate for the Treatment of Osteoporosis in Men

1 reference

12 December 2020

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

12 December 2020

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

12 December 2020

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

1 reference

12 December 2020

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group

1 reference

12 December 2020

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center

1 reference

12 December 2020

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

12 December 2020

Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer

1 reference

12 December 2020

Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer

1 reference

12 December 2020

Hip fracture prediction in elderly men and women: validation in the Rotterdam study.

1 reference

12 December 2020

Current status of intermittent androgen suppression in the treatment of prostate cancer

1 reference

12 December 2020

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

12 December 2020

Intermittent androgen suppression in the management of prostate cancer

1 reference

12 December 2020

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

1 reference

12 December 2020

Total androgen blockade: the United States experience.

1 reference

12 December 2020

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

12 December 2020

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

12 December 2020

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

12 December 2020

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

1 reference

12 December 2020

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Long-Term Combined Androgen Blockade Alone for Localized Prostate Cancer

1 reference

12 December 2020

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

12 December 2020

Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.

1 reference

12 December 2020

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer

1 reference

12 December 2020

Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR)

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Intermittent androgen blockade in prostate cancer: rationale and clinical experience

1 reference

12 December 2020

Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer

1 reference

12 December 2020

Is disease flare a problem?

1 reference

12 December 2020

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

12 December 2020

The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer

1 reference

12 December 2020

A pilot study of intermittent androgen deprivation in advanced prostate cancer

1 reference

12 December 2020

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

12 December 2020

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group

1 reference

12 December 2020

Intermittent endocrine therapy for advanced prostate cancer

1 reference

12 December 2020

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

12 December 2020

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

12 December 2020

Intermittent endocrine therapy of prostate cancer

1 reference

12 December 2020

Estramustine Phosphate Sodium

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1476080&resulttype=core&format=json

10 May 2020

PubMed publication ID

16986000

1 reference